Muvalaplin, a drug under development at Eli Lilly, lowered lipoprotein levels by 65 percent, according to results published Aug. 28 in JAMA.
The medication could be the first treatment for lipoprotein, a genetic marker of cholesterol that increases the risk of heart attack and stroke. Lipoprotein is stickier than LDL cholesterol, and drugs indicated for LDL aren’t as effective for lipoprotein, meaning muvalaplin has potential to be the first drug to tackle “sticky” cholesterol.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
